Medeon Biodesign (ROCO:6499) EPS (Basic): NT$-7.24 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
68 GF Score
Price NT$69.80
GF Value NT$107.08
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medeon Biodesign EPS (Basic)?

Medeon Biodesign ROCO:6499 -1.69% 68 EPS (Basic) is NT$-7.24 as of Dec. 2025. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Medeon Biodesign's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$-1.54. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-7.24.

Medeon Biodesign's EPS (Diluted) for the three months ended in Dec. 2025 was NT$-1.54. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-7.24.

Medeon Biodesign's EPS without NRI for the three months ended in Dec. 2025 was NT$-1.53. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -7.24.

During the past 3 years, the average EPS without NRI Growth Rate was -15.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Medeon Biodesign's highest 3-Year average EPS without NRI Growth Rate was 2.10% per year. The lowest was -58.70% per year. And the median was -15.80% per year.

Medeon Biodesign  (ROCO:6499) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medeon Biodesign EPS (Basic) Related Terms

Medeon Biodesign EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign EPS (Basic) Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.43 -4.66 -12.96 -8.74 -7.24

Medeon Biodesign Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -1.91 -1.91 -1.88 -1.54
ROCO:6499
68GF Score
Medeon Biodesign Inc ROCO:6499
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Medeon Biodesign's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-668.062-0)/92.334
=-7.24

Medeon Biodesign's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-137.115-0)/90.036
=-1.52

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-7.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-7.24 mean?
Medeon Biodesign (ROCO:6499) has a EPS (Basic) of NT$-7.24 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medeon Biodesign and its competitors.
Is Medeon Biodesign's EPS (Basic) too high?
Medeon Biodesign's current EPS (Basic) is NT$-7.24. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's EPS (Basic) compare to ISRG and BDX?
Medeon Biodesign's EPS (Basic) of NT$-7.24 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Medeon Biodesign and its competitors. Medeon Biodesign's current EPS (Basic) is NT$-7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$69.80 — trading 34.8% below its estimated fair value. The current EPS (Basic) is NT$-7.24. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current EPS (Basic) is NT$-7.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$69.80 is trading 34.8% below its estimated GF Value™ of NT$107.08. GuruFocus considers Medeon Biodesign to be Significantly Undervalued.

Key valuation signals for ROCO:6499:

  • EPS (Basic): NT$-7.24
  • GF Value™: NT$107.08 vs. price of NT$69.80 (34.8% below fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score

Get the complete analysis for ROCO:6499

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.80
Price
NT$107.08
GF Value